Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02

BACKGROUND: Receptor tyrosine kinases such as epidermal growth factor receptors (EGFRs) and their downstream signaling pathways such as the Ras-Raf-mitogen-activated protein kinase (MAPK) pathway play important roles in glioblastoma (GBM). This study investigated the safety, pharmacokinetics, and ef...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neurooncol Adv
Asıl Yazarlar: Chen, Huanwen, Kuhn, John, Lamborn, Kathleen R, Abrey, Lauren E, DeAngelis, Lisa M, Lieberman, Frank, Robins, H Ian, Chang, Susan M, Yung, W K Alfred, Drappatz, Jan, Mehta, Minesh P, Levin, Victor A, Aldape, Kenneth, Dancey, Janet E, Wright, John J, Prados, Michael D, Cloughesy, Timothy F, Wen, Patrick Y, Gilbert, Mark R
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2020
Konular:
Clinical Investigations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7668489/
https://ncbi.nlm.nih.gov/pubmed/33235994
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa124
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller